Scarica l'app Stockscreener
5.72
0.88%
0.05
Dopo l'orario di chiusura:
5.72
Precedente Chiudi:
$5.67
Aprire:
$5.51
Volume 24 ore:
625.72K
Relative Volume:
0.64
Capitalizzazione di mercato:
$423.78M
Reddito:
$531.00K
Utile/perdita netta:
$-99.96M
Rapporto P/E:
-2.6096
EPS:
-2.1919
Flusso di cassa netto:
$-98.96M
1 W Prestazione:
+1.24%
1M Prestazione:
-19.78%
6M Prestazione:
-14.63%
1 anno Prestazione:
+94.23%
Intervallo 1D:
$5.48
$5.83
Intervallo di 1 settimana:
$5.01
$6.0736
Portata 52W:
$1.45
$10.99
Lexeo Therapeutics Inc Stock (LXEO) Company Profile
Nome
Lexeo Therapeutics Inc
Settore
Industria
Telefono
(212) 547-9879
Indirizzo
345 PARK AVENUE SOUTH, NEW YORK
Compare LXEO vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LXEO
Lexeo Therapeutics Inc
|
5.72 | 423.78M | 531.00K | -99.96M | -98.96M | -2.1919 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Lexeo Therapeutics Inc Stock (LXEO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-18 | Iniziato | Raymond James | Strong Buy |
| 2025-11-20 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-10-15 | Iniziato | Guggenheim | Buy |
| 2025-07-31 | Iniziato | Oppenheimer | Outperform |
| 2024-06-13 | Iniziato | Robert W. Baird | Outperform |
| 2024-06-06 | Iniziato | H.C. Wainwright | Buy |
| 2023-11-28 | Iniziato | Chardan Capital Markets | Buy |
| 2023-11-28 | Iniziato | JP Morgan | Overweight |
| 2023-11-28 | Iniziato | Leerink Partners | Outperform |
| 2023-11-28 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-11-28 | Iniziato | Stifel | Buy |
Mostra tutto
Lexeo Therapeutics Inc Borsa (LXEO) Ultime notizie
Lexeo Therapeutics (LXEO) Price Target Increased by 19.77% to 21.29 - MSN
LXEO Technical Analysis & Stock Price Forecast - Intellectia AI
Published on: 2026-04-02 23:43:24 - baoquankhu1.vn
LXEO News | LEXEO THERAPEUTICS INC (NASDAQ:LXEO) - ChartMill
Oppenheimer Reaffirms Their Buy Rating on Lexeo Therapeutics, Inc. (LXEO) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Lexeo Therapeutics, Inc. (LXEO), Bicara Therapeutics Inc. (BCAX) and Compass Therapeutics (CMPX) - The Globe and Mail
Will Lexeo Therapeutics (NASDAQ:LXEO) Spend Its Cash Wisely? - finance.yahoo.com
Cantor Fitzgerald reiterates Lexeo Therapeutics stock Overweight rating By Investing.com - Investing.com Canada
Cantor Fitzgerald reiterates Lexeo Therapeutics stock Overweight rating - Investing.com
Lexeo Therapeutics 2025 Annual Report: Advancing Genetic Medicine for Cardiovascular Diseases - Minichart
Big Picture: Should I invest in Lexeo Therapeutics Inc before earnings2026 AllTime Highs & Verified High Yield Trade Plans - baoquankhu1.vn
Lexeo Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Lexeo Therapeutics Advances Cardiac Gene Therapies, Strengthens Finances - TipRanks
Lexeo Therapeutics (NASDAQ:LXEO) Announces Quarterly Earnings Results - MarketBeat
Lexeo Therapeutics | 10-K: Annual report - Moomoo
Gene therapy advances at Lexeo Therapeutics (NASDAQ: LXEO) target heart disease - Stock Titan
Lexeo Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - MarketScreener
Runway into 2028 as Lexeo (NASDAQ: LXEO) pushes pivotal cardiac gene therapies - Stock Titan
Lexeo Therapeutics : Corporate Presentation March 2026 - marketscreener.com
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights - ChartMill
US Market Wrap: Is Lexeo Therapeutics Inc on track to beat earnings2026 Volume & Weekly High Momentum Picks - baoquankhu1.vn
Vanguard realignment leads to separate LXEO holdings reporting (LXEO) - Stock Titan
Aug Mood: Will Lexeo Therapeutics Inc outperform its industry peers2026 Action & Capital Efficient Trading Techniques - baoquankhu1.vn
Lexeo Therapeutics (LXEO) Gets a PT Cut to $13 by H.C. Wainwright Due to Equity Raise - MSN
Wall Street Recap: Is Lexeo Therapeutics Inc. subject to activist investor interestTrade Risk Report & Precise Buy Zone Tips - baoquankhu1.vn
Hedge Fund Moves: Does Lexeo Therapeutics Inc have declining or rising EPSMarket Growth Report & Long-Term Safe Return Strategies - baoquankhu1.vn
Published on: 2026-03-22 00:04:32 - baoquankhu1.vn
Oppenheimer Initiates Coverage of Lexeo Therapeutics (LXEO) with Outperform Recommendation - msn.com
Is Lexeo Therapeutics Inc forming a bullish divergence2026 EndofYear Setup & Daily Profit Focused Screening - baoquankhu1.vn
Lexeo Therapeutics Inc expected to post a loss of 31 cents a shareEarnings Preview - TradingView
[Form 4] Lexeo Therapeutics, Inc. Insider Trading Activity - Stock Titan
Lexeo Therapeutics (LXEO) CEO acquires 2,623 shares via employee stock plan - Stock Titan
Signal Recap: Can Lexeo Therapeutics Inc ride the EV waveMarket Trend Summary & Proven Capital Preservation Methods - baoquankhu1.vn
Lexeo Therapeutics (LXEO) Projected to Post Earnings on Monday - MarketBeat
LEXEO THERAPEUTICS Q4 2025 Earnings Preview: Recent $LXEO Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Lexeo Therapeutics (NASDAQ:LXEO) Shares Up 10.4%What's Next? - MarketBeat
Sectors Review: Is Lexeo Therapeutics Inc. subject to activist investor interestWeekly Trade Summary & Low Volatility Stock Suggestions - baoquankhu1.vn
Is Lexeo Therapeutics Inc a cyclical or defensive stockMarket Volume Report & Daily Growth Stock Investment Tips - baoquankhu1.vn
Wall Street rallies behind Lexeo Therapeutics (LXEO)’s gene therapy pipeline - MSN
Published on: 2026-03-07 09:09:20 - baoquankhu1.vn
LXEO Earnings History & Surprises | EPS & Revenue Results | LEXEO THERAPEUTICS INC (NASDAQ:LXEO) - ChartMill
Lexeo Therapeutics to Participate in the Leerink Global Healthcare Conference - The Manila Times
Genetic medicine firm Lexeo to stream Leerink conference chat - Stock Titan
Nasdaq Moves: Can Lexeo Therapeutics Inc ride the EV waveRate Cut & Safe Capital Growth Trade Ideas - baoquankhu1.vn
Lexeo Therapeutics Highlights FA and PKP2 Cardiac Gene Therapy Progress at Oppenheimer Conference - MarketBeat
Cantor Fitzgerald Remains a Buy on Lexeo Therapeutics, Inc. (LXEO) - The Globe and Mail
LXEO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Earnings Update: Is Lexeo Therapeutics Inc forming a bullish divergenceProduct Launch & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
Profit Review: Is Lexeo Therapeutics Inc forming a bullish divergenceShare Buyback & Risk Controlled Stock Alerts - baoquankhu1.vn
Narinder Pal Bhalla Net Worth (2026) - GuruFocus
Lexeo Therapeutics Inc Azioni (LXEO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):